Nicole D. Schartz

This study shows that inhibiting C5aR1 reduces excessive synaptic pruning and synaptic loss in AD mouse models, improving LTP in an age and region-dependent manner.

Pharmacologic inhibition of C5aR1 suppresses disease-enhancing processes and promotes disease mitigating pathways in an aggressive model of Alzheimer's disease.

The paper shows that C5aR1 antagonism reduces amyloid load and dystrophic neurites in a mouse model of Alzheimer's disease, shifting microglial polarization toward a neuroprotective phenotype.

This study shows that modulating C5a-C5aR1 signaling in Alzheimer's disease models affects cognitive decline and gene expression related to inflammation and astrocyte activation.